SCM
MNPR icon

Silverarc Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Silverarc Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,488
Closed -$2.38M – 85
2026
Q1 		$2.38M Buy
+43,488
New +$2.63M 0.24% 57

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Silverarc Capital Management's MNPR Position: Q2 2026 in Review

Silverarc Capital Management sold out of Monopar Therapeutics (MNPR) in Q2 2026, closing a stake of 43,488 shares — an estimated $2.38M sold.

Silverarc Capital Management first reported a position in MNPR in Q1 2026 and held it in 1 quarter. The position peaked at $2.38M in Q1 2026. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Silverarc Capital Management reported no remaining Monopar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 43,488 Monopar Therapeutics shares in Q2 2026, an estimated $2.38M.
  • Silverarc Capital Management first reported a position in Monopar Therapeutics in Q1 2026 and held it in 1 quarter.
  • Silverarc Capital Management's Monopar Therapeutics position peaked at $2.38M in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.